- Home
- TOPS vs CMMB Comparison
TOPS vs CMMB Comparison
Compare TOPS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- CMMB
- Stock Information
- Founded
- TOPS 2000
- CMMB 2004
- Country
- TOPS Greece
- CMMB Israel
- Employees
- TOPS N/A
- CMMB N/A
- Industry
- TOPS Marine Transportation
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- CMMB Health Care
- Exchange
- TOPS Nasdaq
- CMMB Nasdaq
- Market Cap
- TOPS 27.6M
- CMMB 23.0M
- IPO Year
- TOPS 2004
- CMMB N/A
- Fundamental
- Price
- TOPS $5.30
- CMMB $1.37
- Analyst Decision
- TOPS
- CMMB Strong Buy
- Analyst Count
- TOPS 0
- CMMB 2
- Target Price
- TOPS N/A
- CMMB $8.50
- AVG Volume (30 Days)
- TOPS 6.6K
- CMMB 115.4K
- Earning Date
- TOPS 06-03-2025
- CMMB 05-15-2025
- Dividend Yield
- TOPS N/A
- CMMB N/A
- EPS Growth
- TOPS N/A
- CMMB N/A
- EPS
- TOPS 1.09
- CMMB N/A
- Revenue
- TOPS $86,127,000.00
- CMMB N/A
- Revenue This Year
- TOPS $9.90
- CMMB N/A
- Revenue Next Year
- TOPS N/A
- CMMB N/A
- P/E Ratio
- TOPS $4.87
- CMMB N/A
- Revenue Growth
- TOPS 3.83
- CMMB N/A
- 52 Week Low
- TOPS $5.12
- CMMB $0.78
- 52 Week High
- TOPS $14.24
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- TOPS 33.93
- CMMB 56.90
- Support Level
- TOPS $5.11
- CMMB $1.31
- Resistance Level
- TOPS $5.97
- CMMB $1.47
- Average True Range (ATR)
- TOPS 0.20
- CMMB 0.09
- MACD
- TOPS -0.05
- CMMB 0.01
- Stochastic Oscillator
- TOPS 20.87
- CMMB 68.18
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.